Juan Andres - 30 Jul 2021 Form 4 Insider Report for Moderna, Inc. (MRNA)

Role
Chief Technical Operations and Quality Officer
Signature
/s/ Brian Sandstrom, as Attorney-in-Fact
Issuer symbol
MRNA
Transactions as of
30 Jul 2021
Net transactions value
-$6,892,550
Form type
4
Filing time
03 Aug 2021, 16:23:28 UTC
Previous filing
30 Jul 2021
Next filing
06 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MRNA Common Stock Options Exercise $61,050 +5,000 $12.21* 5,000 30 Jul 2021 Direct F1
transaction MRNA Common Stock Sale $1,734,500 -5,000 -100% $346.90 0 30 Jul 2021 Direct F1
transaction MRNA Common Stock Options Exercise $61,050 +5,000 $12.21* 5,000 02 Aug 2021 Direct F1
transaction MRNA Common Stock Options Exercise $122,100 +10,000 +200% $12.21* 15,000 02 Aug 2021 Direct F1
transaction MRNA Common Stock Sale $5,402,250 -15,000 -100% $360.15 0 02 Aug 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.2% $0.000000 399,822 30 Jul 2021 Common Stock 5,000 $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -5,000 -1.3% $0.000000 394,822 02 Aug 2021 Common Stock 5,000 $12.21 Direct F1, F2
transaction MRNA Stock Option (Right to Buy) Options Exercise $0 -10,000 -2.5% $0.000000 384,822 02 Aug 2021 Common Stock 10,000 $12.21 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020, and amended on May 12, 2021.
F2 25% of this option vested and became exercisable on August 1, 2018 with the remainder vesting in 12 equal quarterly installments thereafter.

Remarks:

Chief Technical Operations and Quality Officer